^
BIOMARKER:

EGFR amplification

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
Phase 2
AstraZeneca
Recruiting
Last update posted :
01/12/2022
Initiation :
01/09/2019
Primary completion :
09/30/2022
Completion :
09/30/2022
EGFR • MET
|
EGFR mutation • EGFR L858R • MET amplification • EGFR exon 19 deletion • EGFR amplification • MET overexpression
|
Tagrisso (osimertinib) • Orpathys (savolitinib)
Phase 2/3
AbbVie
Active, not recruiting
Last update posted :
01/11/2022
Initiation :
12/07/2015
Primary completion :
06/30/2022
Completion :
06/30/2022
EGFR • MGMT
|
EGFR mutation • EGFR amplification • EGFRvIII mutation
|
temozolomide • depatuxizumab mafodotin (ABT-414)
Phase 1
University of Pennsylvania
Not yet recruiting
Last update posted :
01/11/2022
Initiation :
06/19/2022
Primary completion :
12/19/2024
Completion :
12/19/2039
EGFR
|
EGFR amplification • EGFR wild-type • IDH wild-type
|
cyclophosphamide • fludarabine IV • TmEGFR/IL13Rα2 01 CAR-T
Phase 2
Jonsson Comprehensive Cancer Center
Active, not recruiting
Last update posted :
01/06/2022
Initiation :
11/28/2018
Primary completion :
11/01/2022
Completion :
11/01/2023
EGFR • TP53
|
TP53 mutation • EGFR mutation • EGFR amplification
|
Tagrisso (osimertinib)
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
12/16/2021
Initiation :
12/02/2021
Primary completion :
11/01/2023
Completion :
11/01/2023
HER-2
|
MET amplification • EGFR amplification
|
Rybrevant (amivantamab-vmjw)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
12/03/2021
Initiation :
07/06/2021
Primary completion :
06/01/2025
Completion :
06/01/2025
EGFR • MGMT • TERT
|
EGFR amplification • TERT promoter mutation • TERT mutation • IDH wild-type
|
Tecentriq (atezolizumab) • Actemra IV (tocilizumab)
Phase 2a
Merck KGaA, Darmstadt, Germany
Completed
Last update posted :
11/09/2021
Initiation :
10/30/2018
Primary completion :
09/30/2020
Completion :
05/27/2021
EGFR • PD-L1
|
PD-L1 expression • EGFR amplification • EGFR expression
|
Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • Bavencio (avelumab)
Phase 1
Bicara Therapeutics
Recruiting
Last update posted :
10/22/2021
Initiation :
06/01/2020
Primary completion :
12/31/2022
Completion :
06/01/2023
EGFR • PD-L1 • KRAS
|
KRAS mutation • EGFR mutation • EGFR amplification • KRAS G12D • PD-L1 negative • KRAS G13 • KRAS G12 • EGFR negative • RAS wild-type
|
Keytruda (pembrolizumab) • BCA101
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
10/21/2021
Initiation :
03/13/2014
Primary completion :
10/19/2021
Completion :
10/19/2022
EGFR
|
EGFR amplification
|
lapatinib
Phase 2
Kadmon Corporation, LLC
Completed
Last update posted :
09/22/2021
Initiation :
06/01/2016
Primary completion :
04/30/2020
Completion :
04/30/2020
EGFR
|
EGFR amplification
|
tesevatinib (KD019)
Phase 2
Peking University
Not yet recruiting
Last update posted :
07/13/2021
Initiation :
07/01/2021
Primary completion :
10/01/2022
Completion :
05/01/2023
EGFR
|
EGFR amplification
|
Gilotrif (afatinib) • Tuoyi (toripalimab)
Phase 1
Crimson Biopharm Inc.
Not yet recruiting
Last update posted :
06/21/2021
Initiation :
08/01/2021
Primary completion :
07/01/2023
Completion :
07/01/2024
EGFR
|
EGFR mutation • EGFR amplification • IDH wild-type
|
CM93
Phase 2
National Cancer Center, Korea
Recruiting
Last update posted :
05/14/2021
Initiation :
09/01/2019
Primary completion :
12/31/2022
Completion :
12/31/2023
EGFR
|
EGFR amplification
|
paclitaxel • rogaratinib (BAY 1163877) • GC-1118A
Phase 2
Chimerix
Withdrawn
Last update posted :
04/30/2021
Initiation :
02/15/2021
Primary completion :
12/31/2022
Completion :
06/30/2023
EGFR
|
EGFR amplification • EGFR expression • EGFRvIII expression
|
ONC201
Phase 1
University of Pennsylvania
Completed
Last update posted :
03/03/2021
Initiation :
03/11/2019
Primary completion :
02/27/2021
Completion :
02/27/2021
EGFR • MGMT • TERT
|
EGFR amplification • MGMT promoter methylation • TERT promoter mutation • EGFRvIII expression • TERT mutation • IDH wild-type
|
Keytruda (pembrolizumab) • CART-EGFRvIII T cells
Phase 1
Santosh Kesari
Active, not recruiting
Last update posted :
02/12/2021
Initiation :
12/01/2016
Primary completion :
12/01/2021
Completion :
12/01/2022
EGFR
|
EGFR mutation • EGFR amplification
|
Gilotrif (afatinib)
Phase 2
University of Pennsylvania
Recruiting
Last update posted :
02/05/2021
Initiation :
06/23/2020
Primary completion :
06/01/2025
Completion :
06/01/2025
MGMT • TERT
|
EGFR amplification • TERT promoter mutation • TERT mutation • IDH wild-type
|
retifanlimab (INCMGA0012) • ragifilimab (INCAGN1876)
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
01/25/2021
Initiation :
10/31/2017
Primary completion :
10/01/2022
Completion :
10/01/2023
HER-2 • KRAS • ERBB3 • ERBB4
|
KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification • ERBB3 mutation • ERBB4 mutation
|
Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)
Phase 2
Shanghai Changzheng Hospital
Recruiting
Last update posted :
12/30/2020
Initiation :
07/01/2019
Primary completion :
08/31/2021
Completion :
12/31/2021
EGFR
|
EGFR amplification
|
Erbitux (cetuximab) • capecitabine • oxaliplatin • TheraCIM (nimotuzumab)
Phase 1
University Hospital, Basel, Switzerland
Completed
Last update posted :
12/08/2020
Initiation :
11/16/2018
Primary completion :
11/01/2020
Completion :
11/01/2020
EGFR
|
EGFR amplification
|
Erbitux (cetuximab)
Phase 2
Boehringer Ingelheim
Completed
Last update posted :
11/18/2020
Initiation :
06/09/2016
Primary completion :
09/24/2018
Completion :
09/02/2019
EGFR • HER-2 • ERBB3
|
HER-2 amplification • HER-2 mutation • EGFR amplification • ERBB3 mutation
|
Gilotrif (afatinib)
Phase 1/2
AbbVie
Completed
Last update posted :
09/03/2020
Initiation :
08/24/2015
Primary completion :
08/27/2020
Completion :
08/27/2020
EGFR
|
EGFR amplification
|
temozolomide • depatuxizumab mafodotin (ABT-414)
Phase 2
Annick Desjardins
Completed
Last update posted :
08/05/2020
Initiation :
02/01/2016
Primary completion :
07/10/2019
Completion :
04/27/2020
EGFR
|
EGFR amplification
|
futuximab/modotuximab (Sym004)
Phase 2
Samsung Medical Center
Recruiting
Last update posted :
07/15/2020
Initiation :
04/30/2018
Primary completion :
12/31/2020
Completion :
07/31/2021
EGFR
|
EGFR amplification
|
GC-1118A
Phase 1
Hutchison Medipharma Limited
Recruiting
Last update posted :
06/16/2020
Initiation :
01/26/2018
Primary completion :
06/30/2020
Completion :
08/31/2020
EGFR
|
EGFR amplification
|
epitinib (HMPL-813)
Phase 2
AbbVie
Completed
Last update posted :
05/25/2020
Initiation :
02/17/2015
Primary completion :
06/24/2019
Completion :
06/24/2019
EGFR
|
EGFR mutation • EGFR amplification • EGFRvIII mutation
|
temozolomide • lomustine • depatuxizumab mafodotin (ABT-414)
Phase N/A
AbbVie
No Longer Available
Last update posted :
07/15/2019
EGFR
|
EGFR mutation • EGFR amplification • EGFRvIII mutation
|
depatuxizumab mafodotin (ABT-414)
Phase 2
Peking University
Active, not recruiting
Last update posted :
06/11/2019
Initiation :
04/28/2019
Primary completion :
01/01/2020
Completion :
05/01/2020
EGFR
|
EGFR amplification
|
Gilotrif (afatinib)
Phase 2
Samsung Medical Center
Recruiting
Last update posted :
05/20/2019
Initiation :
12/03/2014
Primary completion :
12/01/2019
Completion :
12/01/2020
EGFR
|
EGFR amplification • EGFR overexpression
|
gefitinib
Phase N/A
Tongji Hospital
Recruiting
Last update posted :
03/26/2019
Initiation :
01/01/2019
Primary completion :
12/31/2021
Completion :
12/31/2022
EGFR • TP53 • PTEN • MGMT • TERT • ATRX
|
TP53 mutation • EGFR mutation • EGFR amplification • PTEN mutation • ATRX mutation • EGFR mutation + PTEN mutation • TERT mutation
Phase 2
Massachusetts General Hospital
Completed
Last update posted :
08/16/2018
Initiation :
04/01/2010
Primary completion :
09/01/2015
Completion :
09/01/2015
EGFR
|
EGFR amplification
|
Vizimpro (dacomitinib)
Phase 1
Wake Forest University Health Sciences
Completed
Last update posted :
07/02/2018
Initiation :
04/01/2007
Primary completion :
03/01/2009
Completion :
03/01/2009
EGFR • CCND1
|
EGFR amplification • CCND1 expression
|
erlotinib • 5-fluorouracil • oxaliplatin
Phase 1
AbbVie
Completed
Last update posted :
11/21/2017
Initiation :
04/02/2013
Primary completion :
06/19/2017
Completion :
06/19/2017
EGFR
|
EGFR amplification • EGFR expression
|
temozolomide • depatuxizumab mafodotin (ABT-414)
Phase 1/2
AbbVie (prior sponsor, Abbott)
Completed
Last update posted :
11/20/2017
Initiation :
10/01/2012
Primary completion :
11/01/2015
Completion :
11/01/2015
EGFR
|
EGFR amplification • EGFR expression
|
depatuxizumab mafodotin (ABT-414)
Phase 1
Merck KGaA
Completed
Last update posted :
08/23/2017
Initiation :
10/01/2013
Primary completion :
10/01/2015
Completion :
10/01/2015
EGFR
|
EGFR amplification • EGFR expression
|
futuximab/modotuximab (Sym004)
Phase 1
Merck Sharp & Dohme Corp.
Completed
Last update posted :
04/04/2016
Initiation :
02/01/2009
Primary completion :
06/01/2010
Completion :
05/01/2011
EGFR
|
EGFR mutation • EGFR amplification
|
erlotinib • dalotuzumab (MK 0646)
Phase 2
Oncolytics Biotech
Completed
Last update posted :
12/02/2015
Initiation :
03/01/2009
Primary completion :
09/01/2015
Completion :
11/01/2015
EGFR • KRAS
|
KRAS mutation • EGFR mutation • EGFR amplification • EGFR exon 18 mutation
|
carboplatin • paclitaxel • Reolysin (pelareorep)
Phase 1
Pfizer
Completed
Last update posted :
10/28/2015
Initiation :
08/01/2010
Primary completion :
02/01/2014
Completion :
02/01/2014
EGFR • HER-2 • KRAS • ALK • PIK3CA • MET • ROS1
|
KRAS mutation • EGFR mutation • HER-2 amplification • PIK3CA mutation • MET amplification • EGFR amplification • ALK rearrangement • ALK amplification • EGFR mutation + PIK3CA mutation • ALK rearrangement + PIK3CA mutation
|
Xalkori (crizotinib) • Vizimpro (dacomitinib)
Phase 2
Peter MacCallum Cancer Centre, Australia
Recruiting
Last update posted :
07/23/2015
Initiation :
07/01/2015
Primary completion :
12/01/2017
Completion :
12/01/2018
EGFR • HER-2 • KRAS • ALK • ER • PIK3CA • NRAS • PGR • PTEN • HRAS • AKT1 • PIK3R1 • INPP4B • PI3K • PIK3R3
|
KRAS mutation • EGFR mutation • ER positive • HER-2 negative • PIK3CA mutation • EGFR amplification • ALK mutation • AKT1 mutation • PIK3R1 mutation
|
Piqray (alpelisib)
Phase 1
University Health Network, Toronto
Completed
Last update posted :
07/23/2015
Initiation :
09/01/2005
Primary completion :
05/01/2011
EGFR
|
EGFR mutation • EGFR amplification
|
erlotinib • Nexavar (sorafenib)
Phase 1/2
University Health Network, Toronto
Completed
Last update posted :
07/10/2015
Initiation :
05/01/2010
Primary completion :
02/01/2012
Completion :
02/01/2014
EGFR • CD44
|
EGFR mutation • EGFR amplification • EGFR expression • CD44 expression
|
Vizimpro (dacomitinib)
Phase 2
Hoffmann-La Roche
Completed
Last update posted :
11/10/2014
Initiation :
12/01/2007
Primary completion :
09/01/2010
Completion :
09/01/2010
HER-2 • VEGFA • NOS3
|
HER-2 negative • EGFR amplification
|
Avastin (bevacizumab) • docetaxel
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
05/28/2014
Initiation :
07/01/2002
Primary completion :
02/01/2010
Completion :
03/01/2010
EGFR
|
EGFR amplification
|
gefitinib
Phase 3
Samsung Medical Center
Completed
Last update posted :
05/15/2014
Initiation :
01/01/2009
Primary completion :
01/01/2012
Completion :
06/01/2012
EGFR
|
EGFR mutation • EGFR amplification • EGFR expression • AKT1 amplification
|
erlotinib • gemcitabine • oxaliplatin
Phase 2
Genentech, Inc.
Completed
Last update posted :
03/04/2014
Initiation :
07/01/2003
Completion :
10/01/2005
EGFR
|
EGFR amplification
|
erlotinib
Phase 1
Pfizer
Completed
Last update posted :
10/08/2013
Initiation :
07/01/2008
Primary completion :
08/01/2011
Completion :
01/01/2013
EGFR • KRAS
|
KRAS mutation • EGFR mutation • EGFR amplification
|
Vizimpro (dacomitinib) • figitumumab (CP-751,871)
Phase 2
Sun Yat-sen University
Completed
Last update posted :
08/13/2013
Initiation :
09/01/2010
Primary completion :
06/01/2012
Completion :
12/01/2012
EGFR
|
EGFR mutation • EGFR amplification • EGFR expression
|
Erbitux (cetuximab)
Phase 2
Massachusetts General Hospital
Completed
Last update posted :
05/14/2013
Initiation :
09/01/2005
Primary completion :
01/01/2007
Completion :
12/01/2012
EGFR
|
EGFR mutation • EGFR amplification
|
gefitinib
Phase 2
Pfizer
Completed
Last update posted :
02/06/2013
Initiation :
06/01/2006
Primary completion :
01/01/2010
Completion :
01/01/2012
EGFR • KRAS • FLT3 • KIT • PDGFRB • FLT4 • VEGFC
|
KRAS mutation • EGFR mutation • EGFR amplification • EGFR expression • PDGFRB mutation
|
erlotinib • Sutent (sunitinib)